| 000 | 01732 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514220833.0 | ||
| 264 | 0 | _c20050630 | |
| 008 | 200506s 0 0 eng d | ||
| 022 | _a0149-5992 | ||
| 024 | 7 |
_a10.2337/diacare.28.3.757 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiura, Yoshitaka | |
| 245 | 0 | 0 |
_aReplacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. _h[electronic resource] |
| 260 |
_bDiabetes care _cMar 2005 |
||
| 300 |
_a757-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Letter | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xtherapeutic use |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzimidazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzoates _xtherapeutic use |
| 650 | 0 | 4 | _aBiphenyl Compounds |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 |
_aDiabetic Angiopathies _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTelmisartan |
| 650 | 0 | 4 |
_aTetrazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aValine _xanalogs & derivatives |
| 650 | 0 | 4 | _aValsartan |
| 700 | 1 | _aYamamoto, Naoki | |
| 700 | 1 | _aTsunekawa, Shin | |
| 700 | 1 | _aTaguchi, Seiko | |
| 700 | 1 | _aEguchi, Yoko | |
| 700 | 1 | _aOzaki, Nobuaki | |
| 700 | 1 | _aOiso, Yutaka | |
| 773 | 0 |
_tDiabetes care _gvol. 28 _gno. 3 _gp. 757-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2337/diacare.28.3.757 _zAvailable from publisher's website |
| 999 |
_c15409538 _d15409538 |
||